Psychotic Disorders and Schizophrenia
The sponsor’s clinical research includes schizophrenia, schizophrenia spectrum disorders, and other primary psychotic disorders, with interest in symptom control and functional recovery in early and remitted illness.
- Antipsychotic maintenance treatment
- Early-phase schizophrenia
- Schizophrenia spectrum disorders
Research activity in this area is centered in psychiatric care and focuses on adjunctive approaches for persistent symptoms and social functioning.
Cannabidiol in Psychiatric Treatment
The sponsor studies cannabidiol as an add-on intervention in schizophrenia and alcohol dependence, reflecting interest in non-standard therapeutic options within mental health and addiction care.
- Cannabidiol
- Add-on therapy
- Antipsychotic treatment
This area links psychiatry with substance-related disorder research and supports exploration of symptom-oriented adjunctive therapies.
Oxytocin and Social Functioning
Another focus is intranasal oxytocin in schizophrenia spectrum disorders, with attention to psychosocial outcomes and social skill support alongside routine care.
- Intranasal oxytocin
- Psychosocial treatment
- Social skills
The therapeutic interest lies in interventions that may complement psychosocial treatment for patients with enduring social and interpersonal difficulties.
Alcohol Dependence and Craving Reduction
The sponsor also funds research in alcohol dependence, with a clear focus on craving reduction and treatment support for patients receiving standard addiction therapy.
- Alcohol craving
- Naltrexone
- Substance use disorder
This research area combines addiction medicine with interest in adjunctive pharmacological strategies for persistent craving.
